John Y Ho

US Patent:

6491922, Dec 10, 2002

Filed:

Feb 4, 1997

Appl. No.:

08/794500

Inventors:

John L. Ho - New York NY

Assignee:

Cornell Research Foundation, Inc. - Ithaca NY

International Classification:

A61K 39385

US Classification:

4241931, 4242651, 4242691, 514 2

Abstract:

The present invention relates to methods of treating inflammatory diseases, inhibiting production of adhesion molecules on endothelial cells, inhibiting production of nitric oxide synthase by macrophages, inhibiting production of tissue factor by endothelial cells, reversing the inhibitory effects of lipophosphoglycan on endothelial cells or macrophages, and targeting a material to endothelial cells, fibroblasts, or monocytes, by administering lipophosphoglycan or lipophosphoglycan analog. Also disclosed is an isolated DNA molecule suitable for connection to a gene capable of transcription where lipophophoglycan or lipophosphoglycan analogues bind to the DNA molecule and antagonizes transcription of the gene.

US Patent:

20030199012, Oct 23, 2003

Filed:

Jan 31, 2003

Appl. No.:

10/357043

Inventors:

John Ho - New York NY, US

International Classification:

A61K039/40
G01N033/554
G01N033/569
C07H021/04
C12P021/02
C12N001/21
C07K014/35
C07K016/12

US Classification:

435/007320, 424/168100, 435/069300, 435/252300, 435/320100, 530/350000, 536/023700, 530/388400

Abstract:

The present invention relates to a nucleic acid construct having a nucleic acid molecule that encodes a factor suppressing an immune response to in a host subject; an isolated antibody against the protein or polypeptide encoded by the nucleic acid molecule; and uses for the protein and its antibody, including in a method for detection of in a sample of tissue or body fluids; a method of vaccinating a mammal against infection by ; a vaccine for preventing infection and disease of mammals by and for actively immunizing mammals against ; and methods of treating inflammatory disease in mammals.

US Patent:

20050267025, Dec 1, 2005

Filed:

Mar 18, 2005

Appl. No.:

11/083624

Inventors:

John Ho - New York NY, US

International Classification:

A61K038/17

US Classification:

514012000

Abstract:

The present invention relates to a vaccine for preventing infection that contains a polypeptide isolated from that suppresses the immune response and induces IL-10 in a subject infected with , and to methods of treating an inflammatory condition in a mammal, vaccinating a mammal against infection by , and treating a mammal for infection by , which involve providing a nucleic acid molecule encoding the polypeptide isolated from that suppresses the immune response and induces IL-10 in a subject infected with , or the polypeptide itself, and administering the nucleic acid molecule or its encoded polypeptide to a mammal.

US Patent:

56679645, Sep 16, 1997

Filed:

Oct 28, 1994

Appl. No.:

8/331218

Inventors:

John Lap Ho - New York NY

Assignee:

Cornell Research Foundation, Inc. - Ithaca NY

International Classification:

C12Q 170
C12Q 100

US Classification:

435 5

Abstract:

The ability to monitor the progression of human immunodeficiency virus (HIV) infection in patients is paramount to the study of HIV transmission, in predicting the onset and advancement of disease, and evaluating the clinical efficacy of therapeutics. Present methods available to the clinician for the study of HIV pathogenesis employ surrogate markers. Surrogate markers are biological indicators that tend to reflect, to varying extent, the gradual progression of the asymptomatic state to the development of acquired immune deficiency syndrome (AIDS). The most commonly used markers are CD4. sup. + lymphocyte counts and HIV p24 antigen production. The use of markers to evaluate disease progression suffers from a number of limitations. No known marker consistently reflects disease progression in all patients and stages of disease. Moreover, an effective marker must rapidly reflect the changes associated with antiviral therapy.